Blood-testing startup Theranos announced Wednesday that it will close its clinical labs and lay off hundreds of employees.
Theranos CEO Elizabeth Holmes wrote in a statement that the company will close facilities in Pennsylvania, Arizona and California and focus on rebuilding after multiple regulatory investigations into its practices. The move will affect some 340 employees.
“We have a new executive team leading our work toward obtaining FDA clearances, building commercial partnerships, and pursuing publications in scientific journals,” Holmes wrote in a statement on the Theranos website.
Holmes and Theranos developed what it claimed was the first blood test that could diagnose diseases from a single drop of blood, but an October 2015 Wall Street Journal report citing former Theranos employees questioned the accuracy of the company’s testing device.
The company announced in April that it was under investigation by the U.S. Securities and Exchange Commission and the U.S. Attorney’s Office for the Northern District of California. Theranos has also faced probes from the Food and Drug Administration, the Centers for Medicare and Medicaid Services and two state health departments.
More Must-Reads from TIME
- Why Trump’s Message Worked on Latino Men
- What Trump’s Win Could Mean for Housing
- The 100 Must-Read Books of 2024
- Sleep Doctors Share the 1 Tip That’s Changed Their Lives
- Column: Let’s Bring Back Romance
- What It’s Like to Have Long COVID As a Kid
- FX’s Say Nothing Is the Must-Watch Political Thriller of 2024
- Merle Bombardieri Is Helping People Make the Baby Decision
Contact us at letters@time.com